Pfizer (NYSE: PFE) is a 173-year-old company with a huge portfolio of products. This year, Pfizer has dropped about 16%, in line with the S&P 500. In fact, there are three reasons Pfizer stock could crush the broader market in 2023.
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
NEW YORK, November 28, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business; Kevin Sullivan, Global Specialty Care & U.S. President; and Navin Katyal, U.S. Commercial and Global Business Lead for mRNA Portfolio, at the Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 4:20 p.m. EST.